BioNTech (NASDAQ:BNTX) Shares Gap Down to $100.53

BioNTech SE (NASDAQ:BNTX)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $100.53, but opened at $96.38. BioNTech shares last traded at $100.39, with a volume of 166,704 shares traded.

Analysts Set New Price Targets

Several research analysts have recently commented on BNTX shares. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research note on Wednesday, August 7th. Evercore ISI started coverage on BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a report on Tuesday, August 27th. Finally, TD Cowen cut their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $109.09.

BioNTech Price Performance

The stock has a market cap of $24.16 billion, a P/E ratio of 201.06 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The business has a 50 day simple moving average of $85.08 and a 200-day simple moving average of $89.26.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the previous year, the firm earned ($0.86) EPS. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. On average, sell-side analysts forecast that BioNTech SE will post -2.8 EPS for the current year.

Institutional Trading of BioNTech

Several large investors have recently added to or reduced their stakes in the stock. Candriam S.C.A. grew its stake in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Neuberger Berman Group LLC bought a new stake in BioNTech during the fourth quarter worth about $1,562,000. US Bancorp DE increased its stake in shares of BioNTech by 420.7% during the fourth quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after purchasing an additional 23,119 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in BioNTech by 17.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock worth $19,301,000 after acquiring an additional 26,777 shares in the last quarter. Finally, Harding Loevner LP purchased a new stake in shares of BioNTech in the fourth quarter worth $410,984,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.